利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

77 条记录 (耗时 0.082 秒)

    Cyclic amino acid derivatives as cell adhesion inhibitors
    21.
    发明授权
    Cyclic amino acid derivatives as cell adhesion inhibitors 失效
    环状氨基酸衍生物作为细胞粘附抑制剂

    公开(公告)号：US06271252B1

    公开(公告)日：2001-08-07

    申请号：US09554989

    申请日：2000-05-23

    申请人： Linda Chang ,  William K. Hagmann ,  Malcolm MacCoss

    发明人： Linda Chang ,  William K. Hagmann ,  Malcolm MacCoss

    IPC分类号： A61K31401

    CPC分类号： C07D493/08 ,  C07C311/19 ,  C07C311/20 ,  C07C2601/14 ,  C07D207/16

    摘要： Cyclic amino acid derivatives of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.

    摘要翻译： 式I的环状氨基酸衍生物是VLA-4和/或α4β7的拮抗剂，因此可用于抑制或预防细胞粘附和细胞粘附介导的病理学。 这些化合物可以配制成药物组合物，并且适用于治疗哮喘，过敏，炎症，多发性硬化以及其它炎性和自身免疫性疾病。

    Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection
    25.
    发明申请
    Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection 有权
    用于治疗RNA依赖性RNA病毒感染的核苷芳基磷酰胺化物

    公开(公告)号：US20100234316A1

    公开(公告)日：2010-09-16

    申请号：US12223940

    申请日：2007-02-12

    申请人： Malcolm MacCoss ,  David B. Olsen ,  Monica Donghi ,  Cristina Gardelli ,  Steven Harper ,  Malte Meppen ,  Frank Narjes ,  Barbara Pacini

    发明人： Malcolm MacCoss ,  David B. Olsen ,  Monica Donghi ,  Cristina Gardelli ,  Steven Harper ,  Malte Meppen ,  Frank Narjes ,  Barbara Pacini

    IPC分类号： A61K31/7068 ,  C07H19/10 ,  A61P31/14

    CPC分类号： C07H19/06

    摘要： The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.

    摘要翻译： 本发明提供结构式（I）的核苷芳基氨基磷酸酯，其是RNA依赖性RNA病毒聚合酶抑制剂的前体。 这些化合物是RNA依赖性RNA病毒复制抑制剂的前体，可用于治疗RNA依赖性RNA病毒感染。 它们特别可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂的前体，作为HCV复制抑制剂的前体和/或治疗丙型肝炎感染。 本发明还描述了单独或与其它对RNA依赖性RNA病毒感染，特别是HCV感染有活性的试剂组合的含有这种核苷芳基氨基磷酸酯的药物组合物。 还公开了本发明的核苷芳基氨基磷酸酯抑制RNA依赖性RNA聚合酶，抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。

    Prodrugs of herpes TK inhibitors
    30.
    发明授权
    Prodrugs of herpes TK inhibitors 失效
    疱疹TK抑制剂的前药

    公开(公告)号：US5663175A

    公开(公告)日：1997-09-02

    申请号：US353475

    申请日：1994-12-09

    申请人： Richard L. Tolman ,  John D. Karkas ,  Derek Von Langen ,  Malcolm MacCoss

    发明人： Richard L. Tolman ,  John D. Karkas ,  Derek Von Langen ,  Malcolm MacCoss

    IPC分类号： C07D473/00 ,  C07F9/6561 ,  A61K31/52

    CPC分类号： C07D473/00 ,  C07F9/65616 ,  Y10S514/931 ,  Y10S514/934

    摘要： Certain prodrugs such as ##STR1## are useful in the inhibition of herpes virus thymidine kinase, the prevention or treatment of recurrent infection by herpes virus, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing or treating recurrent infection by herpes virus are also described.

    摘要翻译： 某些前药如“IMAGE”可用于抑制疱疹病毒胸苷激酶，预防或治疗疱疹病毒的复发性感染，作为化合物，药学上可接受的盐，药物组合物成分，无论是否与其它抗病毒药物组合， 免疫调节剂，抗生素或疫苗。 还描述了预防或治疗疱疹病毒复发性感染的方法。